Capmatinib and nazartinib shows promise in EGFR-mutated Lung Cancer resistant to prior treatments
EGFR Positive UK shared a post on X:
“Capmatinib and nazartinib shows promise in patients with EGFR-mutated Lung Cancer resistant to prior treatments.
‘The combination demonstrated anti tumour activity,’ indicating potential as a new treatment strategy.”
Capmatinib plus nazartinib in patients with EGFR-mutated non-small cell lung cancer
Authors: Enriqueta Felip, Giulio Metro, Ross A Soo, Jürgen Wolf, Benjamin J Solomon, Daniel Sw Tan, Andrea Ardizzoni, Dae Ho Lee, Lecia V Sequist, Fabrice Barlesi, Santiago Ponce-Aix, Delvys Rodriguez Abreu, Maria Rosario Garcia Campelo, Mette Sprauten, Leslie O’Sullivan Djentuh, Nathalie Smith, Aline Jary, Riccardo Belli, Sabine Glaser, Mike Zou, Xiaoming Cui, Monica Giovannini, and James Chih-Hsin Yang.
Source: EGFR Positive UK/X
-
ESMO 2024 Congress
September 13-17, 2024
-
ASCO Annual Meeting
May 30 - June 4, 2024
-
Yvonne Award 2024
May 31, 2024
-
OncoThon 2024, Online
Feb. 15, 2024
-
Global Summit on War & Cancer 2023, Online
Dec. 14-16, 2023